Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: Melinta Starts Trial for STD Antibiotic


Hartford (01.09.2014) Aids Weekly Plus

Hartford recently reported that the New Haven, Conn., biotech firm Melinta Therapeutics began Phase 3 trials of the drug deloflaxin to compare its safety and effectiveness in treating gonorrhea to existing treatments. According to a 2012 CDC report, new antibiotic treatments are needed to halt a four-fold increase in gonorrhea throughout the next seven years, since drug resistance has reduced the recommended treatment for the disease to just one combination of ceftriaxone and azithromyacin. During 2012, Congress signed into law the GAIN Act, which provides incentives to biotech firms that develop antibiotics for drug-resistant pathogens—if deloflaxin receives approval for gonorrhea treatment, the medication would receive 10 years of market exclusivity—double the usual timeframe.


Copyright © 2014 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in January 13, 2014. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.